Kernicteric Jaundice - Causes, Treatment & When to See a Doctor

```html

What is Kernicteric Jaundice?

Kernicteric jaundice, also called bilirubin encephalopathy, is a serious form of neonatal jaundice in which high levels of unconjugated (indirect) bilirubin cross the immature blood‑brain barrier and deposit in the basal ganglia and other brain regions. The term “kernicteric” combines the Greek words kernos (kernel) and icterus (yellow), reflecting the yellow‑brown staining seen in the brain on autopsy. While all newborns develop some jaundice, kernicteric jaundice represents a toxic level of bilirubin that can cause permanent neurological injury if not treated promptly.

Most cases occur in the first two weeks of life, with the highest risk between 3–7 days after birth. Early recognition and rapid reduction of serum bilirubin are essential to prevent long‑term complications such as cerebral palsy, auditory dysfunction, and vision problems.

Common Causes

Several conditions raise the risk that an infant’s bilirubin will climb to kernicteric levels. The most frequent causes are listed below; many newborns have more than one contributing factor.

• Hemolytic disease of the newborn (HDN) – maternal‑fetal blood group incompatibility (ABO or Rh) leads to rapid red‑cell destruction.
• Neonatal hemolysis – G6PD deficiency, hereditary spherocytosis, or other red‑cell membrane disorders.
• Breast‑feeding jaundice – inadequate milk intake in the first 48‑72 hours reduces stool output and bilirubin excretion.
• Breast‑feeding jaundice (breast‑milk jaundice) – substances in breast milk (e.g., beta‑glucuronidase) increase enterohepatic circulation of bilirubin after the first week.
• Prematurity – immature liver enzymes (particularly UDP‑glucuronosyltransferase) limit bilirubin conjugation.
• Crigler‑Najjar syndrome type I – a rare genetic deficiency of bilirubin‑glucuronosyltransferase causing severe unconjugated hyperbilirubinemia.
• Physiologic neonatal jaundice – normal breakdown of fetal hemoglobin combined with limited hepatic clearance; can become dangerous if bilirubin rises too quickly.
• Sepsis or severe infection – increases bilirubin production and interferes with hepatic uptake.
• Hypothyroidism – slows liver metabolism and bilirubin conjugation.
• Medications – certain drugs (e.g., sulfonamides, tetracyclines, chloramphenicol) can displace bilirubin from albumin or impair liver function.

Associated Symptoms

When bilirubin reaches neurotoxic concentrations, the infant may develop a spectrum of neurological signs that evolve rapidly. Early symptoms are often subtle, making close observation critical.

• Yellow discoloration of the skin and sclera (jaundice) that spreads from face to chest, abdomen, and extremities.
• Rising bilirubin levels despite appropriate phototherapy or exchange transfusion.
• Lethargy or excessive sleepiness – the baby is difficult to arouse.
• Poor feeding – reduced sucking, low milk intake.
• High‑pitched cry or “inconsolable” crying due to irritability.
• Hypotonia (floppy muscles) progressing to stiffness (hypertonia) especially in the neck and trunk.
• Abnormal movements: opisthotonus (arched back), seizure‑like jerks, or dystonic posturing of the limbs.
• Auditory dysfunction – later in life, children may develop sensorineural hearing loss.
• Visual problems – difficulty tracking objects or nystagmus.

When to See a Doctor

Because kernicteric jaundice can develop quickly, parents and caregivers should act at the first sign of abnormal jaundice or neurological change.

• If the baby’s skin or eyes look yellow beyond the first 24 hours of life (especially after 48 hours in term infants).
• When jaundice spreads to the abdomen, thighs, or palms.
• Infants who are difficult to wake, have a weak cry, or are markedly sleepy.
• Any feeding problems – failure to gain weight, poor latch, or intake < 60 mL per feeding.
• Any sudden change in muscle tone (floppiness or stiffness) or abnormal movements.
• If the baby is born preterm (< 37 weeks), has a known blood‑type incompatibility, or a family history of bilirubin‑related disorders.

When any of these signs appear, seek medical evaluation **immediately**—preferably within the same day.

Diagnosis

The evaluation of suspected kernicteric jaundice combines clinical assessment with laboratory and imaging tools.

1. Physical Examination

• Assessment of jaundice intensity using the “Kramer rule” (skin yellowing progresses in 5 zones).
• Neurological exam for tone, reflexes, and responsiveness.

2. Serum Bilirubin Measurement

• Total serum bilirubin (TSB) – the primary screening test; values > 20 mg/dL in term infants or > 15 mg/dL in preterm infants raise concern.
• Fractionation to differentiate unconjugated vs. conjugated bilirubin; kernicteric jaundice involves markedly elevated **indirect** bilirubin.

3. Risk‑Stratification Tools

• American Academy of Pediatrics (AAP) Phototherapy/Hypothermia Guidelines nomograms.
• Gestational‑age specific bilirubin nomograms (Bhutani curve).

4. Additional Laboratory Tests (as indicated)

• Blood type & Coombs test – to detect hemolytic disease.
• Complete blood count (CBC) – for anemia or hemolysis.
• G6PD assay – if ethnicity or family history suggests deficiency.
• Thyroid function tests – if hypothyroidism is suspected.
• Liver function panel – to rule out cholestasis.

5. Neuroimaging (rare, but sometimes used)

• Transcranial ultrasound or MRI may be ordered if there is concern for brain injury after bilirubin peaks.

6. Auditory Screening

• Otoacoustic emissions (OAE) or auditory brainstem response (ABR) testing is recommended after discharge for infants who had bilirubin > 20 mg/dL.

Treatment Options

Therapy aims to **lower serum bilirubin quickly** and **prevent bilirubin from entering the brain**. The choice of treatment depends on bilirubin level, infant age, gestational age, and underlying cause.

1. Phototherapy

• First‑line treatment for most cases. Blue‑green light (≈460 nm) converts unconjugated bilirubin into water‑soluble isomers (photo‑isomers) that can be excreted without conjugation.
• Types: conventional overhead lamps, fiber‑optic blankets, or LED biliblankets.
• Goal: reduce TSB by at least 2–3 mg/dL per hour in term infants.
• Monitor bilirubin every 4–6 hours and adjust intensity as needed.

2. Exchange Transfusion

• Indicated when bilirubin is at or above “exchange level” (≈ 20–25 mg/dL in term infants) *or* when rapid decline is not achieved with phototherapy and the infant shows neuro‑toxic signs.
• Procedure replaces the infant’s blood with donor blood, removing bilirubin and antibodies.
• Requires neonatal intensive care unit (NICU) support and expert staff.

3. Intravenous Immunoglobulin (IVIG)

• Used primarily for immune‑mediated hemolysis (e.g., Rh incompatibility) to reduce hemolysis and bilirubin production.
• Administered at 1 g/kg over 2 hours; may reduce the need for exchange transfusion.

4. Medications

• Phenobarbital – occasionally used in chronic conditions (e.g., Crigler‑Najjar type II) to induce hepatic UDP‑glucuronyltransferase.
• **Avoid** drugs that displace bilirubin from albumin (e.g., sulfonamides, ceftriaxone).

5. Supportive Measures

• Ensure adequate hydration and nutrition – encourage frequent breastfeeding or formula feeds (10–12 mL/kg/hour).
• Expose infant to natural daylight (if safe) as adjunct to phototherapy.
• Maintain a warm environment to prevent hypothermia, which can worsen jaundice.

6. Long‑Term Follow‑Up

• Neurodevelopmental assessments at 6 months, 12 months, and yearly thereafter.
• Audiology and ophthalmology evaluations for infants who had bilirubin > 20 mg/dL.

Prevention Tips

While some risk factors (prematurity, genetics) cannot be eliminated, many steps reduce the likelihood of bilirubin reaching dangerous levels.

• Early and frequent feeding – aim for 8–12 breastfeeds per day in the first week; consider supplemental expressed milk or formula if output is insufficient.
• Monitor newborn weight daily for the first 5–7 days; loss > 10 % of birth weight warrants evaluation.
• Assess bilirubin levels before discharge (usually at 24 hours for term, 48 hours for preterm infants).
• Educate parents on the visual signs of jaundice and when to call the pediatrician.
• For mothers with known blood‑type incompatibility, provide prophylactic anti‑D immunoglobulin (Rh‑negative mothers) and close post‑natal monitoring.
• Screen for G6PD deficiency in at‑risk ethnic groups before discharge.
• Avoid unnecessary medications that may increase bilirubin binding competition (e.g., ceftriaxone in neonates).
• Consider early phototherapy for infants with risk factors even if bilirubin is borderline.

Emergency Warning Signs

References

• Mayo Clinic. “Neonatal Jaundice.” https://www.mayoclinic.org. Accessed April 2026.
• American Academy of Pediatrics. “Management of Hyperbilirubinemia in the Full‑Term Newborn.” Pediatrics, 2022; 149(2):e2021055805.
• National Institute of Child Health and Human Development (NICHD). “Kernicterus and Bilirubin Encephalopathy.” https://www.nichd.nih.gov. Accessed April 2026.
• Cleveland Clinic. “Kernicterus (Bilirubin Encephalopathy).” https://my.clevelandclinic.org. Accessed April 2026.
• World Health Organization. “Neonatal Jaundice: Guidelines for Management.” WHO Guideline 2021.
• Kaplan M, et al. “Bilirubin Neurotoxicity: Mechanisms and Clinical Implications.” *Journal of Perinatology*, 2021; 41(8):1994‑2002.

``` This HTML document provides a thorough, patient‑friendly overview of kernicteric jaundice, organized with semantic headings, actionable lists, and clear guidance on when to seek urgent care.